Belfast Celerion CPU

Celerion

Cystic Fibrosis

Fibrosis

Asthma

Pulmonary Fibrosis

Hypertension

Bronchiectasis

Respiratory Distress Syndrome

Obstructive Lung Diseases

Communicable Diseases

Lung Diseases

Celecoxib

PTI-428

FDL169

Amlodipine

CSL787

CTX-4430

Fluticasone Propionate

FDL176

PTI-801

Nicotine

Philip Morris

Celtaxsys

Flatley Discovery Lab

Imperial Brands

Proteostasis Therapeutics

2A Pharma

AbbVie

Allergan

Boehringer Ingelheim

British American Tobacco

condition

allSponsorName

Modern Biosciences

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Celerion | Belfast Celerion CPU

Site insights

Active trials

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Trial sponsors